



Bal Pharma Limited

01/04/2019

To,
The Manager-Listing
National Stock Exchange of India Limited
Mumbai,

To,
The Manager-Listing
Bombay Stock Exchange Limited
Mumbai,

Dear Sir,

Sub:- Disclosure under Regulation 30 of SEBI (Substantial Acquisition of shares and Takeovers) Regulations, 2011.


With reference to the above, we submit to the exchange disclosures received from the promoter and the promoter group of the Company in compliance with the provisions of regulation 30(2) of SEBI (Substantial Acquisition of shares and Takeovers) Regulations, 2011 for the Financial Year ended 31st March, 2019.

Please take the same on record.

Thanking You,

For Bal Pharma Limited

Authorised Signatory



CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58

Email : Info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph: 41570813 / 19 Fax: 41570820



Bal Pharma Limited

PART- B

For Bal Pharma Limited

Authorised Signatory



Intertek



014

CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58

Email : Info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph: 41570813 / 19 Fax: 41570820

To,

31.03.2019

The Manager-Listing
NSE
Mumbai

Dear Sir,


Sub;- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulations, 2011

Ref: Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial year ending 31st March, 2019 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation, 2011.

Thanking You,



SHAILESH SIROYA

Copy to:

BAL PHARMA LIMITED
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) Bombay Stock Exchange Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders:			
a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC	NA		
Or			
b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	SHAILESH SIROYA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year, holding of:	1345459	9.49%	9.49%
a) Shares			
b) Voting Rights (otherwise than by shares)			
c) Warrants,			
d) Convertible Securities			
e) any other instrument that would entitle the holder to receive shares in the TC.			
TOTAL	1345459	9.49%	9.49%


(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore

Date: 31.03.2019


SHAILESH SIROYA

To,

31.03.2019

The Manager-Listing
NSE
Mumbai

Dear Sir,


Sub;- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulations, 2011

Ref: Scrip Code BAL PHARMA

With reference to the above cited regulation of SEBI, I hereby submit my disclosure regarding my shareholding as on Financial year ending 31st March, 2019 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation, 2011.

Thanking You,


ANITA SIROYA

Copy to:

BAL PHARMA LIMITED
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011


1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) Bombay Stock Exchange Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders:			
a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.	NA		
Or			
b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	ANITA SIROYA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year, holding of:			
a) Shares	10,49,220	7.40%	7.40%
b) Voting Rights (otherwise than by shares)			
c) Warrants,			
d) Convertible Securities			
e) any other instrument that would entitle the holder to receive shares in the TC.			
TOTAL	10,49,220	7.40%	7.40%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore
Date: 31.03.2019


ANITA SIROYA

To,

31.03.2019

The Manager-Listing
NSE
Mumbai

Dear Sir,

Sub;- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulations, 2011

Ref: Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial year ending 31st March, 2019 in BAL PHARMA LIMITED, Bangalore.


Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation, 2011.

Thanking You,

For MICRO LABS LIMITED

For MICRO LABS LIMITED

Authorised Signatory


Company Secretary

Copy to:

BAL PHARMA LIMITED
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC) Bal Pharma Limited

2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed
a) Bombay Stock Exchange Limited, Mumbai.
b) National Stock Exchange of India Limited, Mumbai.

3. Particulars of the Shareholders:

a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC

NA

Or

b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.

MICRO LABS LIMITED

4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year, holding of:			
a) Shares	13,10,836	9.25%	9.25%
b) Voting Rights (otherwise than by shares)			
c) Warrants,			
d) Convertible Securities			
e) any other instrument that would entitle the holder to receive shares in the TC.			
TOTAL	13,10,836	9.25%	9.25%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore
Date: 31.03.2019

For MICRO LABS LIMITED
For MICRO LABS LIMITED

Authorized Signatory

To,

31.03.2019

The Manager-Listing
NSE
Mumbai

Dear Sir,

Sub;- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulations, 2011

Ref: Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI, I hereby submit my disclosure regarding my shareholding as on Financial year ending 31st March, 2019 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation, 2011.

Thanking You,



ANAND SURANA

Copy to:

BAL PHARMA LIMITED
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) Bombay Stock Exchange Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.

3. Particulars of the Shareholders:

a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.

NA

Or

b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.

ANAND SURANA


4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares.	% w.r.t. total share /voting capital wherever applicable.	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year, holding of:			
a) Shares	5,25,686	3.71%	3.71%
b) Voting Rights (otherwise than by shares)			
c) Warrants,			
d) Convertible Securities			
e) any other instrument that would entitle the holder to receive shares in the TC.			
TOTAL	5,25,686	3.71%	3.71%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore
Date: 31.03.2019



ANAND SURANA

To,

31.03.2019

The Manager-Listing
NSE
Mumbai

Dear Sir,


Sub;- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulations, 2011

Ref: Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial year ending 31st March, 2019 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation, 2011.

Thanking You,


DILIP SURANA

Copy to:

BAL PHARMA LIMITED
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) Bombay Stock Exchange Limited, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.

3. Particulars of the Shareholders:

a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC

NA

Or

b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.

DILIP SURANA


4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year, holding of:			
a) Shares	4,74,994	3.35%	3.35%
b) Voting Rights (otherwise than by shares)			
c) Warrants,			
d) Convertible Securities			
e) any other instrument that would entitle the holder to receive shares in the TC.			
TOTAL	4,74,994	3.35%	3.35%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore
Date: 31.03.2019


DILIP SURANA

To,

31.03.2019

The Manager-Listing
NSE
Mumbai

Dear Sir,


Sub;- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulations, 2011

Ref: Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial year ending 31st March, 2019 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation, 2011.

Thanking You,



ARCHANA SURANA

Copy to:

BAL PHARMA LIMITED
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) Bombay Stock Exchange Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.

3. Particulars of the Shareholders:

a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC

NA

Or

b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.

ARCHANA SURANA

4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year, holding of:			
a) Shares	2,84,996	2.01%	2.01%
b) Voting Rights (otherwise than by shares)			
c) Warrants,			
d) Convertible Securities			
e) any other instrument that would entitle the holder to receive shares in the TC.			
TOTAL	2,84,996	2.01%	2.01%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore
Date: 31.03.2019


ARCHANA SURANA

To,

31.03.2019

The Manager-Listing
NSE
Mumbai

Dear Sir,


Sub;- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulations, 2011

Ref: Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial year ending 31st March, 2019 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation, 2011.

Thanking You,

A handwritten signature in black ink, appearing to read 'Monica', followed by a long horizontal flourish.

MONICA SURANA

Copy to:

BAL PHARMA LIMITED
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) Bombay Stock Exchange Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders:			
a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC	NA		
Or			
b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	MONICA SURANA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year, holding of:			
a) Shares	1,79,909	1.27%	1.27%
b) Voting Rights (otherwise than by shares)			
c) Warrants,			
d) Convertible Securities			
e) any other instrument that would entitle the holder to receive shares in the TC.			
TOTAL	1,79,909	1.27%	1.27%


(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore

Date: 31.03.2019


MONICA SURANA

To,

31.03.2019

The Manager-Listing
NSE
Mumbai

Dear Sir,


Sub:- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulations, 2011

Ref: Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial year ending 31st March, 2019 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation, 2011.

Thanking You,



DILIP SURANA (HUF)

Copy to:

BAL PHARMA LIMITED
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) Bombay Stock Exchange Limited, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders:			
a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC	NA		
Or			
b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	DILIP SURANA (HUF)		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 of the year, holding of:			
a) Shares	1,69,995	1.20%	1.20%
b) Voting Rights (otherwise than by shares)			
c) Warrants,			
d) Convertible Securities			
e) any other instrument that would entitle the holder to receive shares in the TC.			
TOTAL	1,69,995	1.20%	1.20%


(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore

Date: 31.03.2019


DILIP SURANA (HUF)

To,

31.03.2019

The Manager-Listing
NSE
Mumbai

Dear Sir,


Sub;- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulations, 2011

Ref: Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial year ending 31st March, 2019 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation, 2011.

Thanking You,



SUBBA RAO PRASANNA

Copy to:

BAL PHARMA LIMITED
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) Bombay Stock Exchange Limited, Mumbai. b) National Stock Exchange of India Ltd, Mumbai.		
3. Particulars of the Shareholders: a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC Or b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	NA SUBBA RAO PRASANNA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) any other instrument that would entitle the holder to receive shares in the TC.	20,200	0.14%	0.14%
TOTAL	20,200	0.14%	0.14%


(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore

Date: 31.03.2019


SUBBA RAO PRASANNA

To,

31.03.2019

The Manager-Listing
NSE
Mumbai

Dear Sir,


Sub;- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulations, 2011

Ref: Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial year ending 31st March, 2019 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation, 2011.

Thanking You,



CHANDRAPRAKASH DHEERAJMAL SIROYA

Copy to:

BAL PHARMA LIMITED
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011


1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) Bombay Stock Exchange Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders:			
a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC	NA		
Or			
b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	CHANDRAPRAKASH DHEERAJMAL SIROYA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year, holding of:			
a) Shares	4,86,420	3.43%	3.43%
b) Voting Rights (otherwise than by shares)			
c) Warrants,			
d) Convertible Securities			
e) any other instrument that would entitle the holder to receive shares in the TC.			
TOTAL	4,86,420	3.43%	3.43%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore
Date : 31.03.2019


CHANDRAPRAKASH DHEERAJMAL SIROYA

To,

31.03.2019

The Manager-Listing
NSE
Mumbai

Dear Sir,


Sub;- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulations, 2011

Ref: Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial year ending 31st March, 2019 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation, 2011.

Thanking You,



ANITA CHANDRAPRAKASH SIROYA

Copy to:

BAL PHARMA LIMITED
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	Bal Pharma Limited
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) Bombay Stock Exchange Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.

3. Particulars of the Shareholders:

a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.

NA

Or

b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.

ANITA CHANDRAPRAKASH SIROYA

4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year, holding of:			
a) Shares	1,22,687	0.87%	0.87%
b) Voting Rights (otherwise than by shares)			
c) Warrants,			
d) Convertible Securities			
e) any other instrument that would entitle the holder to receive shares in the TC.			
TOTAL	1,22,687	0.87%	0.87%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Anita Chandraprakash Siroya

Place: Bangalore
Date: 31.03.2019

ANITA CHANDRAPRAKASH SIROYA

To,

31.03.2019

The Manager-Listing
NSE
Mumbai

Dear Sir,


Sub;- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulations, 2011

Ref: Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial year ending 31st March, 2019 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation, 2011.

Thanking You,



JIVI DHEERAJMAL SIROYA

Copy to:

BAL PHARMA LIMITED
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC) Bal Pharma Limited

2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed a) Bombay Stock Exchange Limited, Mumbai.
b) National Stock Exchange of India Limited, Mumbai.

3. Particulars of the Shareholders:

a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC

NA

Or

b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.

JIVI DHEERAJMAL SIROYA

4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year, holding of:			
a) Shares	46,080	0.33%	0.33%
b) Voting Rights (otherwise than by shares)			
c) Warrants,			
d) Convertible Securities			
e) any other instrument that would entitle the holder to receive shares in the TC.			
TOTAL	46,080	0.33%	0.33%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

JIVI D SIROYA

To,

31.03.2019

The Manager-Listing
NSE
Mumbai

Dear Sir,


Sub;- Disclosure as per Regulation 30(2) of SEBI (SAST) Regulations, 2011

Ref: Scrip Code BALPHARMA

With reference to the above cited regulation of SEBI. I hereby submit my disclosure regarding my shareholding as on Financial year ending 31st March, 2019 in BAL PHARMA LIMITED, Bangalore.

Request you to kindly take the disclosure on records and treat this as compliance with Regulation 30(2) of SEBI (SAST) Regulation, 2011.

Thanking You,


SHRENIK D SIROYA

Copy to:

BAL PHARMA LIMITED
5th Floor, Lakshmi Narayan Complex,
10/1, Palace Road, Bangalore-560052.

FORMAT FOR DISCLOSURES UNDER REGULATION 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011


1. Name of the Target Company (TC)	Bal Pharma Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	a) Bombay Stock Exchange Limited, Mumbai. b) National Stock Exchange of India Limited, Mumbai.		
3. Particulars of the Shareholders: a) Name of the person(s) together with persons acting in concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC Or b) Name of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	NA SHRENIK SIROYA		
4. Particulars of the shareholding of person(s) mentioned at (3) above.	Number of Shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31 st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) any other instrument that would entitle the holder to receive shares in the TC.	000	00%	00%
TOTAL	000	00%	00%

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

Place: Bangalore
Date: 31.03.2019


SHRENIK D SIROYA